79. Tanghetti E, Werschler W, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0. 045% lotion for once-daily treatment of moderateto- severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70-77. doi: 10.36849/JDD.2020.3977
80. Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0. 045% lotion and tazarotene 0. 1% cream in the treatment of moderateto- severe acne vulgaris. J Drugs Dermatol. 2019;18(6):54.
81. Jarratt M, Werner CP, Alió Saenz AB. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Clin Drug Investig. 2013;33(4):283-289. doi: 10.1007/ s40261-013-0065-1
82. Kircik L. Efficacy and safety of tazarotene lotion, 0. 045% in the treatment of truncal acne vulgaris. J Drugs Dermatol. 2022;21(7):713-716. doi: 10.36849/JDD.6967
83. Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. Journal of Dermatological Treatment. 2021;32(4):391-398. doi: 10.1080/09546634.2019.1668907
84. Johnson SM, Chavda R, DuBois JC. Subject satisfaction with trifarotene 50 μg/g cream in the treatment of facial and truncal acne vulgaris: a case series. Dermatol Ther (Heidelb). 2020;10(5):1165- 1173. doi: 10.1007/s13555-020-00417-4
85. Draelos Z, Tanghetti E, Werschler W, et al. In vitro rheology predicts improved spreadability of tazarotene 0. 045% lotion versus trifarotene 0. 005% cream. J Drugs Dermatol. 2022;21(3):250-257. doi: 10.36849/JDD.6703
80. Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0. 045% lotion and tazarotene 0. 1% cream in the treatment of moderateto- severe acne vulgaris. J Drugs Dermatol. 2019;18(6):54.
81. Jarratt M, Werner CP, Alió Saenz AB. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Clin Drug Investig. 2013;33(4):283-289. doi: 10.1007/ s40261-013-0065-1
82. Kircik L. Efficacy and safety of tazarotene lotion, 0. 045% in the treatment of truncal acne vulgaris. J Drugs Dermatol. 2022;21(7):713-716. doi: 10.36849/JDD.6967
83. Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. Journal of Dermatological Treatment. 2021;32(4):391-398. doi: 10.1080/09546634.2019.1668907
84. Johnson SM, Chavda R, DuBois JC. Subject satisfaction with trifarotene 50 μg/g cream in the treatment of facial and truncal acne vulgaris: a case series. Dermatol Ther (Heidelb). 2020;10(5):1165- 1173. doi: 10.1007/s13555-020-00417-4
85. Draelos Z, Tanghetti E, Werschler W, et al. In vitro rheology predicts improved spreadability of tazarotene 0. 045% lotion versus trifarotene 0. 005% cream. J Drugs Dermatol. 2022;21(3):250-257. doi: 10.36849/JDD.6703
AUTHOR CORRESPONDENCE
Leon H. Kircik MD Wedoderm@yahoo.com
